Marker Therapeutics Inc (MRKR)

[ClosetInvestor]

I’m confused how the story Monday can be any better than the article released today. The article had a good summary of the efficacy on pancreatic cancer to date, and yes, it may be working, but it hard to tell how well in a limited trial.

I don’t expect MRKR to release any new or improved data on Monday. They may explain the path forward, and discuss how future trials may be designed, but there isn’t any data that is going to bring back the 27% loss today.